TR200100372T2 - hPPAR gama ve hPPAR alfa aktivatörleri olarak ikame edilmiş oksazoller ve tiazoller - Google Patents

hPPAR gama ve hPPAR alfa aktivatörleri olarak ikame edilmiş oksazoller ve tiazoller

Info

Publication number
TR200100372T2
TR200100372T2 TR2001/00372T TR200100372T TR200100372T2 TR 200100372 T2 TR200100372 T2 TR 200100372T2 TR 2001/00372 T TR2001/00372 T TR 2001/00372T TR 200100372 T TR200100372 T TR 200100372T TR 200100372 T2 TR200100372 T2 TR 200100372T2
Authority
TR
Turkey
Prior art keywords
hppar
oxazoles
gamma
alpha activators
activators
Prior art date
Application number
TR2001/00372T
Other languages
English (en)
Inventor
Loren Collins Jon
Dezube Milana
Alan Oplinger Jeffrey
Mark Willson Timothy
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of TR200100372T2 publication Critical patent/TR200100372T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Bu bulus, (I) formülü bilesiklerini ve bu bilesiklerin totomerik biçimleri, farmasötik açidan kabul edilebilir tuzlari ya da solvatlarini anlatmaktadir. Tercihan, bulusun bilesikleri hPPAR gama ve hPPAR alfa'nin ikili aktivatörleridir.
TR2001/00372T 1998-08-07 1999-08-05 hPPAR gama ve hPPAR alfa aktivatörleri olarak ikame edilmiş oksazoller ve tiazoller TR200100372T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9817118.4A GB9817118D0 (en) 1998-08-07 1998-08-07 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
TR200100372T2 true TR200100372T2 (tr) 2001-09-21

Family

ID=10836805

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00372T TR200100372T2 (tr) 1998-08-07 1999-08-05 hPPAR gama ve hPPAR alfa aktivatörleri olarak ikame edilmiş oksazoller ve tiazoller

Country Status (31)

Country Link
US (1) US6498174B1 (tr)
EP (1) EP1102757B1 (tr)
JP (1) JP2002522426A (tr)
KR (1) KR20010085340A (tr)
CN (1) CN1321152A (tr)
AP (1) AP2001002066A0 (tr)
AR (1) AR020001A1 (tr)
AT (1) ATE264313T1 (tr)
AU (1) AU5731099A (tr)
BR (1) BR9912866A (tr)
CA (1) CA2339773A1 (tr)
CO (1) CO5070570A1 (tr)
CZ (1) CZ2001490A3 (tr)
DE (1) DE69916457T2 (tr)
EA (1) EA200100105A1 (tr)
EE (1) EE200100074A (tr)
ES (1) ES2220110T3 (tr)
GB (1) GB9817118D0 (tr)
HR (1) HRP20010095A2 (tr)
HU (1) HUP0103469A3 (tr)
ID (1) ID29543A (tr)
IL (1) IL141248A0 (tr)
IS (1) IS5840A (tr)
MA (1) MA26668A1 (tr)
NO (1) NO20010628L (tr)
PE (1) PE20000947A1 (tr)
PL (1) PL345882A1 (tr)
SK (1) SK1962001A3 (tr)
TR (1) TR200100372T2 (tr)
WO (1) WO2000008002A1 (tr)
ZA (1) ZA200100983B (tr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60005973T2 (de) 1999-08-27 2004-05-13 Eli Lilly And Co., Indianapolis Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren
EP1939188A1 (en) * 1999-09-22 2008-07-02 Bristol-Myers Squibb Company Oxa-and thiazole derivatives useful as antidiabetic and antiobesity agents
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
GB0002667D0 (en) * 2000-02-04 2000-03-29 Glaxo Group Ltd medicamesnts
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US20040072838A1 (en) 2000-12-20 2004-04-15 Pierette Banker Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
EP1394154A4 (en) * 2001-03-23 2005-05-18 Takeda Pharmaceutical FIVE-GLASS HETEROCYCLIC ALKANIC ACID DERIVATIVE
GB0111523D0 (en) * 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
AU2002342244B2 (en) * 2001-05-15 2005-06-16 F. Hoffmann-La Roche Ag Carboxylic acid substituted oxazole derivatives for use as PPAR-alpha and -gamma activators in the treatment of diabetes
CZ20033450A3 (cs) * 2001-05-29 2004-05-12 Kyotoápharmaceuticaláindustriesźáltd Heterocyklická sloučenina a její lékařské použití
CA2448639A1 (en) * 2001-05-29 2002-12-05 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic derivatives and medicinal use thereof
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200300681A (en) 2001-11-12 2003-06-16 Ono Pharmaceutical Co Carboxylic acid derivative compound and medicament containing same as active ingredient
WO2003059895A1 (en) * 2002-01-17 2003-07-24 Toaeiyo Ltd. Halogenobenzyl aminopropionic acid derivatives
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
US20050119314A1 (en) * 2002-04-05 2005-06-02 Sankyo Company, Limited Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
KR100474202B1 (ko) * 2002-05-04 2005-03-08 강헌중 티아졸 유도체의 제조방법 및 이를 제조하기 위한 중간체
ES2291688T3 (es) 2002-07-03 2008-03-01 F. Hoffmann-La Roche Ag Derivados de oxazol y su empleo como sensibilizadores a la insulina.
AU2003259131A1 (en) 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
ES2350340T3 (es) * 2002-08-30 2011-01-21 F. Hoffmann-La Roche Ag Nuevos compuestos de 2-aril-tiazol como agonistas de pparalfa y ppargamma.
NZ537979A (en) 2002-09-12 2007-08-31 Hoffmann La Roche N-substituted-1H-indol-5-propionic acid compounds as PPAR agonists useful for the treatment of diabetes
AR041481A1 (es) * 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
ATE405560T1 (de) 2002-11-25 2008-09-15 Hoffmann La Roche Indolderivaten
RU2342362C2 (ru) * 2002-11-26 2008-12-27 Шэньчжэнь Чипскрин Байосайенсиз Лтд. Замещенные производные арилалкановой кислоты как пан агонисты рапп с высокой антигипергликемической и антигиперлипидемической активностью
US7192970B2 (en) 2002-11-26 2007-03-20 Chipscreen Biosciences, Ltd. Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity
US7268157B2 (en) * 2002-11-26 2007-09-11 Shenzhen Chipscreen Biosciences, Ltd. Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity
ES2355105T3 (es) 2003-06-20 2011-03-22 F. Hoffmann-La Roche Ag Pirido(2,1-a)isoquinolina como inhibidores de la dpp-iv.
RU2339636C2 (ru) 2003-06-20 2008-11-27 Ф.Хоффманн-Ля Рош Аг Гексагидропиридоизохинолины в качестве ингибиторов дипептидилпептидазы iv (dpp-iv)
WO2005108347A2 (en) 2004-05-06 2005-11-17 The Regents Of The University Of California Substituted enaminones, their derivatives and uses thereof
CN100467456C (zh) * 2004-05-24 2009-03-11 北京摩力克科技有限公司 作为hPPARα和/或hPPARγ激活剂的α-哌嗪取代的苯丙酸衍生物
CN100344618C (zh) * 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物
CN100436430C (zh) * 2004-05-24 2008-11-26 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的烷酰基取代的酪氨酸衍生物
CN1896069B (zh) * 2005-07-15 2011-10-05 中国科学院上海药物研究所 一类取代噻唑-4酮化合物、制备方法和用途
CN101007790B (zh) * 2006-01-27 2011-03-30 北京摩力克科技有限公司 草氨酸衍生物、其制备方法和医药用途
KR101130380B1 (ko) * 2006-06-13 2012-04-23 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 헤테로시클릭 비뉴클레오시드 화합물, 그의 제조방법, 약학적 조성물 및 항바이러스성 약제로서의 용도
GB0719180D0 (en) 2007-10-02 2007-11-14 Cambrex Karlskoga Ab New process
EP2135865A1 (de) 2008-06-17 2009-12-23 Bayer CropScience AG Substituierte 1-(Diazinyl) pyrazol-4-yl-essigsäuren, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
EP2194052A1 (de) 2008-12-06 2010-06-09 Bayer CropScience AG Substituierte 1-(Thiazolyl)- und 1-(Isothiazolyl)pyrazol-4-yl-essigsäuren, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
WO2011073098A1 (de) 2009-12-15 2011-06-23 Bayer Cropscience Ag 1-(heteroaryl)-pyrazol-4-yl-essigsäuren, verfahren zu deren herstellung und deren verwendung als herbizide und pflanzenwachstumsregulatoren
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
WO2022052982A1 (zh) * 2020-09-14 2022-03-17 昭明泽康（北京）生物医药科技有限公司 PPARα（过氧化物酶体增殖物激活受体α）配体在制备药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US6062509A (en) 1994-12-23 2000-05-16 Hexcel Corporation Retrofit centerline luggage bin assemblies compatible with existing aircraft bin supports
JPH08325263A (ja) 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規２−アミノ−３−フェニルプロピオン酸誘導体
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
US6204277B1 (en) * 1996-08-19 2001-03-20 Japan Tobacco Inc. Propionic acid derivatives and applications thereof

Also Published As

Publication number Publication date
HUP0103469A3 (en) 2002-08-28
JP2002522426A (ja) 2002-07-23
AR020001A1 (es) 2002-03-27
HRP20010095A2 (en) 2002-02-28
IL141248A0 (en) 2002-03-10
PL345882A1 (en) 2002-01-14
NO20010628L (no) 2001-04-06
CA2339773A1 (en) 2000-02-17
EA200100105A1 (ru) 2001-08-27
GB9817118D0 (en) 1998-10-07
DE69916457D1 (de) 2004-05-19
DE69916457T2 (de) 2005-04-14
WO2000008002A1 (en) 2000-02-17
EP1102757B1 (en) 2004-04-14
EP1102757A1 (en) 2001-05-30
PE20000947A1 (es) 2000-09-22
HUP0103469A2 (hu) 2002-01-28
AP2001002066A0 (en) 2001-03-31
BR9912866A (pt) 2001-10-30
ZA200100983B (en) 2002-03-05
CN1321152A (zh) 2001-11-07
EE200100074A (et) 2002-06-17
ATE264313T1 (de) 2004-04-15
MA26668A1 (fr) 2004-12-20
CZ2001490A3 (cs) 2001-08-15
NO20010628D0 (no) 2001-02-06
SK1962001A3 (en) 2001-11-06
IS5840A (is) 2001-02-05
CO5070570A1 (es) 2001-08-28
KR20010085340A (ko) 2001-09-07
ES2220110T3 (es) 2004-12-01
AU5731099A (en) 2000-02-28
US6498174B1 (en) 2002-12-24
ID29543A (id) 2001-09-06

Similar Documents

Publication Publication Date Title
TR200100372T2 (tr) hPPAR gama ve hPPAR alfa aktivatörleri olarak ikame edilmiş oksazoller ve tiazoller
ES2188242T3 (es) Derivados de quinolina.
TR200103612T2 (tr) Tiazol ve oksazol türevleri ve farmasötik kullanımları
TR199801255T2 (tr) Vitronektin reseptör antagonistleri.
MY136789A (en) Metalloproteinase inhibitors
TR199901653T2 (tr) Fitalazinonlar.
ES2094716T1 (es) Formula infantil antiregurgitacion.
FI943749A0 (fi) Taksaanijohdannaisten fosfono-oksimetyylieetterit
CL2012002380A1 (es) Compuestos derivados de bezoimidazol, inhibidores de mek; utiles en el tratamiento del cancer.(divisional solicitud cl 521-03)
TR200003004T2 (tr) Kalpain önleyicileri olarak heterosiklik ikame edilmiş amidler
SV2004001485A (es) Composicion de ziprasidona y controles sinteticos ref. pc23201
TR199800773T2 (tr) Trombin inhibitörleri.
IL160051A0 (en) Ecteinascidin derivatives and pharmaceutical compositions containing the same
TR199802318T2 (tr) Kronobiyolojik maddeler olarak benzofuranlar ve benzopiranlar.
TR199800182T1 (tr) 2-oksazolidinon türevlerinin bir kapta sentezi.
TR200101756T2 (tr) Protein kinaz inhibitörleri olarak 4,5-pirazinoksindoller.
DK1042319T3 (da) Dihydrobenzofuraner
NO971219L (no) Behandling og profylakse av pankreatitt
YU18801A (sh) Eletriptan hidrobromid monohidrat
BG104575A (en) Matrix metalloprotease inhibitors
PA8465101A1 (es) Compuestos de triazina
DK1301501T3 (da) Tocotrienolchinoncykliseringsprodukter med antihyperkolesterolvirkning
AP2001002045A0 (en) FKBP inhibitors.
TR200000637T2 (tr) Benzoksazin ve benzotiazin türevleri ve bunların ilaçlarda kullanımı.
NO954892L (no) Heterosyklisk kjemi